SCHEMBL5286375

SCHEMBL5286375

CCc1cc(C(=O)Oc2c(F)c(F)c(F)c(F)c2F)on1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.35
RAB9A P51151 4/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
POLB P06746 2/20 0.35
LMNA P02545 2/20 0.35
NPC1 O15118 3/20 0.34
KMT2A Q03164 3/20 0.34
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MME P08473 2/20 0.33
SMPD1 P17405 1/20 0.33
MEN1 O00255 1/20 0.32
THRB P10828 1/20 0.32
F2RL1 P55085 1/20 0.31
TP53 P04637 1/20 0.31
NFKB1 P19838 1/20 0.31
NFKB2 Q00653 1/20 0.31
RELA Q04206 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5298423 0.88 PPARA (0.35) RAB9AL3MBTL1POLBLMNANPC1
SCHEMBL5283326 0.86 PPARA (0.41) RAB9ALMNANPC1KMT2AMAPT
SCHEMBL5287519 0.84 RAB9A (0.34) RAB9ALMNANPC1MAPTSMN1; SMN2
SCHEMBL5281685 0.79 EPHX2 (0.42) EPHX2RAB9AL3MBTL1TDP1POLB
SCHEMBL14770789 0.78 RAB9A (0.45) RAB9AL3MBTL1TDP1LMNANPC1
SCHEMBL5289527 0.77 SCD (0.31) EPHX2RAB9AL3MBTL1TDP1POLB
SCHEMBL5966739 0.76 ALDH1A1 (0.40) RAB9ATDP1NPC1SMN1; SMN2TSHR
SCHEMBL5966687 0.76 SMN1; SMN2 (0.40) EPHX2POLBLMNAMAPTSMN1; SMN2
SCHEMBL5790429 0.74 EPHX2 (0.36) EPHX2RAB9AL3MBTL1TDP1POLB
SCHEMBL5286514 0.74 SMN1; SMN2 (0.57) RAB9ANPC1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 EPHX2 4143/4885RAB9A 20/4885L3MBTL1 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.